Actidione
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antineoplastic |
| Catalog number | BBF-05900 |
| CAS | 66-81-9 |
| Molecular Weight | 281.35 |
| Molecular Formula | C15H23NO4 |
| Purity | ≥95% |
Online Inquiry
Description
Actidione, an inhibitor of eukaryotic protein synthesis, is an antibiotic isolated from the beers of Streptomycin-producing strains of Streptomyces griseus. Actidione is used as a fungicide and anticancer drug.
Specification
| Synonyms | 4-[(2R)-2-[(1S,3S,5S)-3,5-Dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-piperidinedione; 3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide; Naramycin A; Acti-Aid; Acti-dione; Acti-dione BR; Acti-dione PM; Acti-dione TGF; Actidion; CHX; Cicloheximide; NSC 185; Naramycin; Naramycin Microcapsule D 80; Naramycin NM-MCU 80; TZA; U 4527; Cycloheximide; [1S-[1α(S*),3α,5β]]-4-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidinedione |
| Storage | Store at 2-8°C |
| IUPAC Name | 4-[(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione |
| Canonical SMILES | CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C |
| InChI | InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1 |
| InChI Key | YPHMISFOHDHNIV-FSZOTQKASA-N |
Properties
| Appearance | White to Off-white Solid |
| Antibiotic Activity Spectrum | Neoplastics (Tumor); Fungi |
| Boiling Point | 491.8±10.0°C at 760 mmHg |
| Melting Point | 106-110°C |
| Density | 1.1±0.1 g/cm3 |
| Solubility | Soluble in Chloroform (Slightly), Methanol (Slightly) |
Reference Reading
1. Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae
Bryce W Buchanan, Michael E Lloyd, Sarah M Engle, Eric M Rubenstein J Vis Exp. 2016 Apr 18;(110):53975. doi: 10.3791/53975.
Regulation of protein abundance is crucial to virtually every cellular process. Protein abundance reflects the integration of the rates of protein synthesis and protein degradation. Many assays reporting on protein abundance (e.g., single-time point western blotting, flow cytometry, fluorescence microscopy, or growth-based reporter assays) do not allow discrimination of the relative effects of translation and proteolysis on protein levels. This article describes the use of cycloheximide chase followed by western blotting to specifically analyze protein degradation in the model unicellular eukaryote, Saccharomyces cerevisiae (budding yeast). In this procedure, yeast cells are incubated in the presence of the translational inhibitor cycloheximide. Aliquots of cells are collected immediately after and at specific time points following addition of cycloheximide. Cells are lysed, and the lysates are separated by polyacrylamide gel electrophoresis for western blot analysis of protein abundance at each time point. The cycloheximide chase procedure permits visualization of the degradation kinetics of the steady state population of a variety of cellular proteins. The procedure may be used to investigate the genetic requirements for and environmental influences on protein degradation.
2. Proteome-wide mapping of short-lived proteins in human cells
Jiaming Li, Zhenying Cai, Laura Pontano Vaites, Ning Shen, Dylan C Mitchell, Edward L Huttlin, Joao A Paulo, Brian L Harry, Steven P Gygi Mol Cell. 2021 Nov 18;81(22):4722-4735.e5. doi: 10.1016/j.molcel.2021.09.015. Epub 2021 Oct 8.
Rapid protein degradation enables cells to quickly modulate protein abundance. Dysregulation of short-lived proteins plays essential roles in disease pathogenesis. A focused map of short-lived proteins remains understudied. Cycloheximide, a translational inhibitor, is widely used in targeted studies to measure degradation kinetics for short-lived proteins. Here, we combined cycloheximide chase assays with advanced quantitative proteomics to map short-lived proteins under translational inhibition in four human cell lines. Among 11,747 quantified proteins, we identified 1,017 short-lived proteins (half-lives ≤ 8 h). These short-lived proteins are less abundant, evolutionarily younger, and less thermally stable than other proteins. We quantified 103 proteins with different stabilities among cell lines. We showed that U2OS and HCT116 cells express truncated forms of ATRX and GMDS, respectively, which have lower stability than their full-length counterparts. This study provides a large-scale resource of human short-lived proteins under translational arrest, leading to untapped avenues of protein regulation for therapeutic interventions.
Recommended Products
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
